C-reactive protein promotes bone destruction in human myeloma through the CD32–p38 MAPK–Twist axis

Jing Yang,1,2† Zhiqiang Liu,2,3* Huan Liu,2* Jin He,2 Jianling Yang,2 Pei Lin,4 Qiang Wang,5 Juan Du,6 Wencai Ma,2 Zheng Yin,7 Eric Davis,2 Robert Z. Orlowski,2 Jian Hou,6 Qing Yi5†

Bone destruction is a hallmark of myeloma and affects 80% of patients. Myeloma cells promote bone destruction by activating osteoclasts. In investigating the underlying mechanism, we found that C-reactive protein (CRP), a protein secreted in increased amounts by hepatocytes in response to myeloma-derived cytokines, activated myeloma cells to promote osteoclastogenesis and bone destruction in vivo. In mice bearing human bone grafts and injected with multiple myeloma cells, CRP bound to surface CD32 (also known as FcγRII) on myeloma cells, which activated a pathway mediated by the kinase p38 MAPK and the transcription factor Twist that enhanced the cells’ secretion of osteolytic cytokines. Furthermore, analysis of clinical samples from newly diagnosed myeloma patients revealed a positive correlation between the amount of serum CRP and the number of osteolytic bone lesions. These findings establish a mechanism by which myeloma cells are activated to promote bone destruction and suggest that CRP may be targeted to prevent or treat myeloma-associated bone disease in patients.

INTRODUCTION

More than 80% of patients with multiple myeloma (MM) develop bone disease or destruction that causes pathological fractures, severe bone pain, spinal cord compression, and hypercalcemia (1, 2). In healthy adults, bone is a dynamic tissue that is constantly being remodeled by bone-resorbing osteoclasts (OCs) and bone-forming osteoblasts. In patients with myeloma, bone destruction results from increased OC-mediated bone resorption and decreased osteoblast-mediated bone formation. In particular, the resorbed bone that usually occurs in close proximity to myeloma cells is greatly enhanced and rarely heals (3). OCs arise from hematopoietic monocyctic precursors. The formation of OCs requires the presence of soluble cytokines such as receptor activator of nuclear factor κB (NF-κB) ligand (RANKL) and macrophage colony-stimulating factor (M-CSF), which are produced primarily from bone marrow stromal cells. Myeloma cells enhance osteoclastogenesis by producing a number of cytokines such as RANKL, macrophage inflammatory protein–1α (MIP-1α), and monocyte chemoattractant protein–1 (MCP-1), which can increase OC differentiation and bone resorption activity (4, 5). However, the mechanism underlying how and what activates myeloma cells to produce these cytokines remains unknown.

C-reactive protein (CRP) is an ancient and highly conserved protein of the pentraxin family. It has five identical subunits forming a planar ring that makes the protein highly stable. In healthy young adults, the median concentration of CRP is 0.8 mg/liter, with a range of 0 to 6 mg/liter, but after an acute-phase stimulus, values may increase 10,000-fold, from less than 50 μg/liter to more than 500 mg/liter (6). Plasma CRP is produced primarily in the liver, synthesized by hepatocytes in response to intermediary inflammatory cytokines such as interleukin (IL)–1β and IL-6. CRP can bind to a variety of ligands, including pneumococcal polysaccharides, membrane phospholipids, apoptotic cells, fibronectin, and ribonuclear particles (6). It also binds to C1q and directly activates the classical complement cascade, or binds to Fc gamma receptors (FcγRs), leading to indirect (via classical complement) and direct opsonization (via FcγRs) (7). Through these mechanisms, CRP plays a direct role in a wide range of inflammatory processes and contributes to innate host immunity (8).

Increased levels of CRP are also present in many diseases, including malignancies such as myeloma (9–11), lymphoma (12, 13), and carcinoma (14). High levels of circulating CRP correlate with poor prognosis in myeloma (9, 11) and lymphoma (12). Our previous study showed that CRP enhanced myeloma cell proliferation under stressed conditions and protected myeloma cells from chemotherapy drug–induced apoptosis in a model of human myeloma (15).

Here, through a combination of in vitro, in vivo, and patient studies, we report that CRP has a unique role in myeloma-induced bone disease. Our results show that human CRP binds to CD32/FcγRII on myeloma cells, activates downstream signaling through the p38 mitogen-activated protein kinase (MAPK) and the transcription factor Twist, and promotes the production of osteolytic cytokines from myeloma cells, leading to enhanced myeloma cell–mediated OC differentiation and severe bone resorption in vivo.

RESULTS

CRP promotes lytic bone lesions in myeloma-bearing mice

To determine the effect of CRP on bone destruction under physiological conditions, we injected human recombinant CRP, serum amyloid P component (SAP; an inactive analog of CRP), or phosphate-buffered saline (PBS) (vehicle) into tumor-free severe combined immunodeficient (SCID) or SCID-hu mice in which the SCID mice were implanted with human bone chips. None caused bone destruction in the implanted human bones in the mice (Fig. 1A, left).

We then examined the human origin of CRP on bones in SCID mice xenografted with human myeloma cells. CRP, SAP, or PBS was
injected into SCID-hu mice bearing primary human myeloma cells or SCID mice bearing myeloma cell lines. Lytic bone lesions were detected in the implanted human bone chips of SCID-hu mice 8 weeks after tumor inoculation (Fig. 1A, right), whereas in mice injected with CRP but not SAP or PBS, lytic bone lesions were detected at week 4 after tumor injection. CRP not only accelerated the appearance of bone lesions but also caused more bone destruction, evident by the greater number of lytic bone lesions (Fig. 1A, right), larger lytic area (Fig. 1B), and lower trabecular bone volume (Fig. 1C) compared with controls. Similarly, CRP also resulted in more bone lesions in murine femurs of SCID mice bearing human myeloma cells (Fig. 1, D to F).

To confirm the results, we generated human myeloma cell lines (ARP-1 and MM.1S) that stably produced and secreted human CRP protein. After myeloma was established in SCID mice, these cells also caused more lytic bone lesions in the femurs of SCID mice compared with control myeloma cells (Fig. 1, G and H).

Injection of a neutralizing antibody against human CRP diminished the ability of CRP-producing, but not control, myeloma cells to cause lytic bone lesion in the mice (Fig. 1I). Because these CRP-expressing myeloma cells secreted much lower amounts of CRP than those observed in myeloma patients, it is possible that this autocrine CRP, although at low concentrations but constantly secreted, may accumulate on myeloma cells to effectively bind with the surface receptors to activate signaling in myeloma cells. Thus, these results indicate that human

Fig. 1. CRP enhances induction of bone lesions in myeloma-bearing mice. (A) Representative radiographic images of lytic lesions in the implanted human bones of primary myeloma-bearing severe combined immunodeficient (SCID)-hu mice before (0 w) or at week 4 (4 w) and week 8 (8 w) after injection of primary myeloma cells from one of five patients [Pt MM(multiple myeloma)] and treatment with phosphate-buffered saline (PBS), C-reactive protein (CRP) (20 μg per mouse), or serum amyloid P component (SAP) (20 μg per mouse). Tumor-free mice (no MM) served as controls. (B and C) Histomorphometric analysis of the osteolytic area (B) and bone volume density (IC) assessed as percentage of bone volume over total volume (BV/TV) in the implanted human bones from the mice described in (A) at 8 weeks. (D) Representative radiographic images of lytic bone lesions in the distal femurs of SCID mice injected with one of two myeloma cell lines (ARP-1 or MM.1S) and treated with PBS or CRP (n = 10 mice per group). (E and F) Histomorphometric quantitative analysis of the femurs from the mice described in (D), assessing osteolytic area (E) and BV/TV (F). (G and H) Representative radiographic images of bone lesions (G) and histomorphometric quantitative analysis of osteolytic area (H) in the distal femurs of SCID mice (n = 10 per group) injected with CRP-expressing or vector-control myeloma cells. Arrows indicate osteolytic lesions in mouse femurs. (I) Micro-computed tomography scanning analysis of BV/TV in the femurs of SCID mice bearing CRP-expressing or vector-control myeloma cells, treated with neutralizing antibodies against CRP (αCRP) or control IgG. *P < 0.05, **P < 0.01 by Student’s t test. Images are representative and data are means ± SD of three independent experiments shown.
CRP is capable of promoting myeloma cell–mediated lytic bone disease in vivo.

CRP enhances OC differentiation and bone resorption activity

Myeloma manifests as an osteolytic bone disease mainly due to enhanced OC activity (17). To determine whether CRP affected osteoclastogenesis, primary myeloma-bearing mice were sacrificed 8 weeks after tumor injection, and sections of murine femurs or implanted human bone chips were stained for Tartrate-resistant acid phosphatase (TRAP) to identify OCs. CRP injection resulted in significantly more TRAP+ OCs localized on the trabecular bone surface of the bone-tumor interface (Fig. 2, A and B) and more erosion on trabecular bones (Fig. 2C) in the implanted human bones of myeloma-bearing SCID-hu mice compared with controls. Similarly, more OCs (Fig. 2D) or bone erosion (Fig. 2E) were found in the femurs of myeloma-bearing, CRP-injected SCID mice than those injected with PBS and in mice bearing CRP-producing myeloma cells than those injected with control myeloma cells (Fig. 2F). Injection of CRP-neutralizing antibodies but not control IgG abrogated the enhanced bone destruction produced by CRP-producing myeloma cells (Fig. 2G).

Because the in vivo findings suggested that CRP affected osteoclastogenesis in myeloma-bearing mice, we investigated the role of CRP in OC differentiation in vitro. We observed that adding CRP (5 μg/ml, equal to the average serum levels of CRP in myeloma patients) to cultured OC precursor cells did not induce the formation of mature (multinuclear, TRAP+) OCs (Fig. 3A) or increase the levels of TRAP5b (Fig. 3B), which is an active component of TRAP and is secreted only by mature OCs cocultured with myeloma cells (Fig. 3C), as compared with controls. Coculturing OC precursors with myeloma cells (Pt MM) and treatment with CRP or PBS. Arrows indicate OCs in bone sections. No MM, tumor-free mice. Scale bars, 10 μm. (B and C) Histomorphometric quantitative analysis of (B) the number of OCs on the bone surface (OC. S/BS) and (C) OC-mediated erosion of bone surface, expressed as a percentage of total bone surface (ES/BS), in the implanted human bones of SCID-hu mice that were either tumor-free (−) or bearing primary myeloma cells from one of five patients (Pt MM) and treated with CRP (+) or PBS (−). (D and E) Histomorphometric analysis of (D) OC. S/BS and (E) ES/BS in the femurs of SCID mice (n = 10 per group) bearing myeloma cells and treated with CRP or PBS. (F) OC. S/BS in the femurs of SCID mice bearing CRP-expressing (MM-CRP) or vector-control (MM-Vector) cells. (G) OC. S/BS in the femurs of SCID mice bearing MM-CRP or MM-Vector cells treated with antibodies against CRP (αCRP) or control (IgG). Tumor-free mice (no MM) treated with agents or antibodies served as controls for baseline levels. Data from three independent experiments are shown. \( P < 0.05 \), ** \( P < 0.01 \) by Student's t test.
with CRP-producing human myeloma cells also enhanced mature OC formation (Fig. 3D). Once again, neutralizing CRP in the coculture abrogated CRP-induced, myeloma-mediated OC formation (Fig. 3E). Together, these results indicate that CRP enhances myeloma cell–mediated osteoclastogenesis in vitro.

**CRP stimulates the production of OC activators by myeloma cells**

Because our results showed that addition of CRP to the transwell coculture of OC precursors and myeloma cells induced OC differentiation (Fig. 3), we hypothesized that CRP mediates this effect by up-regulating myeloma cell secretion of cytokines that activate OC differentiation. Microarray analysis of gene profiling identified more than 500 genes with twofold increased expression in CRP-treated myeloma cells compared to PBS-treated cells, including 11 that encode cytokines known to activate osteoclastogenesis: IL-1, MCP-1, IL-11, IL-6, HGF, IL-17, RANKL, M-CSF, BAFF, DcR3, and MIP-1a (fig. S3A). Real-time polymerase chain reaction (PCR) validated that among these cytokines, RANKL, MCP-1, and MIP-1a were highly expressed in CRP-treated myeloma cells, including patient-derived primary myeloma cells and myeloma cell lines ARP-1 and MM.1S, as compared with control myeloma cells (fig. S3B). Not surprisingly, CRP-expressing ARP-1 and MM.1S cells also expressed a higher level of these cytokines as compared with vector-control myeloma cells (fig. S3C).

To determine the involvement of these cytokines in CRP-enhanced OC differentiation, we added neutralizing antibodies against these cytokines to the coculture of OC precursors and myeloma cells in the presence of CRP. The neutralizing antibodies significantly reduced the number of TRAP+ multinuclear OCs (fig. S4A) and level of TRAP5b (fig. S4B). These results indicate that CRP enhances OC differentiation by up-regulating myeloma cell production of OC activators such as RANKL, MCP-1, and MIP-1a.

**CRP binds to CD32 on myeloma cells, promotes cytokine production, and induces OC differentiation**

Because CRP has been shown to bind to FcγRs such as CD32 on human cells including myeloma cells (7, 15), we hypothesized that CD32 expressed on myeloma cells may be involved in CRP-induced myeloma-mediated OC differentiation. We generated stable myeloma cell lines (ARP-1 and MM.1S) with significantly reduced expression of CD32 [herein called CD32-knockdown (CD32-KD); Fig. 4A]. CD32-KD myeloma cells were less able to promote OC differentiation in response to CRP (Fig. 4, B and C). Moreover, CD32-KD myeloma cells caused less bone disease in mice injected with CRP (Fig. 4, D and E), although similar numbers or percentages of CD32-KD and control MM cells were found in the bone marrow of mice (Fig. 4F). As expected, CD32-KD myeloma cells had lower CD32 expression in vivo compared with control cells (Fig. 4G). We then added CRP to cultures of CD32-KD or control ARP-1 or MM.1S cells. The CD32-KD myeloma cells...
had significantly reduced expression (Fig. 5, A and B) and secretion (Fig. 5, C and D) of MCP-1, MIP-1α, and RANKL in response to CRP as compared with control cells.

Because CD32 is involved in various cellular responses, we wanted to exclude the possibility that knockdown of CD32 in myeloma cells affected myeloma cell growth and survival and thereby compromised their ability to secrete osteolytic cytokines that enhance OC differentiation. Our results showed that knockdown of CD32 did not affect myeloma cell growth (Fig. S5A) or survival (Fig. S5B) in vitro or tumor formation and burden in vivo (Fig. S5C).

We also generated stable myeloma cell lines with significantly enhanced CD32 expression (Fig. S6, A and B) to confirm the role of this molecule. CD32-overexpressing myeloma cells expressed (Fig. 5, E and F) and secreted (Fig. 5, G and H) more osteolytic cytokines and displayed enhanced ability to promote OC differentiation in vitro (Fig. S6, C and D), which resulted in severe bone disease in vivo (Fig. S6, E and F) in the presence of CRP. Overexpression of CD32 did not affect myeloma growth and survival in vitro or tumor formation in vivo.

**CRP regulates the expression of osteolytic cytokines in myeloma cells through p38 MAPK–Twist signaling**

Next, we sought to elucidate the molecular mechanism underlying CRP-CD32-mediated signaling pathways that regulate the production of osteolytic cytokines in myeloma cells. First, we analyzed the expression of transcriptional factors in myeloma cell lines by microarray and identified 31 genes that were at least twofold increased in response to CRP (Fig. 6A). We used the software Genomatix (20) to analyze the transcription factor binding sites on the promoter regions of the osteolytic cytokine genes and predicted several potential Twist binding sites. To confirm the results of microarray analysis, we performed a chromatin immunoprecipitation (ChIP) assay to examine the ability of Twist to bind to the promoters of two relevant cytokine (RANKL and MCP-1) genes. We found that Twist was enriched on RANKL and MCP-1 promoters in ARP-1 and MM.1S cells treated with CRP (Fig. 6B). To investigate the importance of Twist in CRP-induced cytokine production by myeloma cells, we used short hairpin RNA (shRNA) to knock down Twist (Twist-KD) abundance in myeloma cells (Fig. 6C). CRP induction of myeloma cell expression of the osteolytic cytokines MCP-1 and RANKL was significantly reduced in Twist-KD myeloma cells as compared to control cells (Fig. 6C). We also cloned the Twist-containing transcription start site of the RANKL and MCP-1 promoters into a luciferase reporter vector. Adding CRP increased the luciferase activity of Luc-RANKL and Luc-MCP-1 in ARP-1 and MM.1S (Fig. 6B). To investigate the importance of Twist in CRP-induced cytokine production by myeloma cells, we used short hairpin RNA (shRNA) to knock down Twist (Twist-KD) abundance in myeloma cells (Fig. 6C). CRP induction of myeloma cell expression of the osteolytic cytokines MCP-1 and RANKL was significantly reduced in Twist-KD myeloma cells as compared to control cells (Fig. 6C). We also cloned the Twist-containing transcription start site of the RANKL and MCP-1 promoters into a luciferase reporter vector. Adding CRP increased the luciferase activity of Luc-RANKL and Luc-MCP-1 in ARP-1 and MM.1S, and truncation of the Twist binding sites in the MCP-1 or RANKL gene promoters significantly reduced the activity (Fig. 6, D and E), suggesting that the potential Twist binding sites for RANKL locate at −1500 to −800 base pairs (bp) of its start codon and those for MCP-1 locate at −350 to −150 bp of its start codon. Next, we performed site-directed mutagenesis on the two putative binding sites for RANKL and three putative binding sites for MCP-1 within each region. Not surprisingly, mutating a single binding site for either RANKL or MCP-1 blocked the transcriptional activation induced by CRP (Fig. 6, D and E). Furthermore, CRP-treated Twist-KD myeloma cells were less able to induce the expression of OC genes in cocultured OC progenitor cells (Fig. 6F), indicating that Twist is crucial to myeloma cell–mediated OC differentiation in response to CRP.

To further examine the effect of CRP on Twist expression, we treated ARP-1 or MM.1S cells with various concentrations (1 to 10 μg/ml) of...
CRP and assessed Twist expression by Western blot. CRP enhanced Twist expression in a dosedependent manner (Fig. 7A). In contrast, Twist expression was reduced in CRP-treated CD32-KD myeloma cells (Fig. 7B). To further investigate the potential downstream targets of Twist, we added various concentrations (1 to 10 μg/ml) of CRP to cultures of myeloma cells and found that CRP enhanced phosphorylation of p38 MAPK but not extracellular signal–regulated kinase (ERK) or NF-κB in a dose-dependent manner (Fig. 7C). CRP promoted the levels of phosphorylated p38 MAPK in control and in CD32-overexpressing myeloma cells but not in CD32-KD myeloma cells (Fig. 7D), indicating that CRP activates the p38 MAPK pathway in myeloma cells through surface CD32. To examine the importance of p38 MAPK in CRP-induced cytokine production in myeloma cells, we added the p38 MAPK–specific inhibitor SB202190 to cultures of myeloma cells along with CRP. SB202190 significantly reduced the expression of osteolytic cytokine mRNAs (Fig. 7E) and reduced CRP-induced Twist protein abundance (Fig. 7F). These results showed that CRP binds to CD32 and activates p38 MAPK–Twist signaling pathways, leading to increased production of osteolytic cytokines by myeloma cells.

**Serum CRP levels significantly and positively correlate with bone lesions in patients with newly diagnosed myeloma**

Finally, we examined the relationship between serum CRP and development of bone disease in patients with myeloma. In newly diagnosed myeloma patients, serum CRP was quantified by enzyme-linked immunosorbent assay (ELISA), and bone disease and the number of bone lesions were detected by x-ray and magnetic resonance imaging. As shown in Fig. 8A, serum CRP level significantly and positively correlated with the number of bone lesions (n = 244; r = 0.6096; P < 0.0001). We examined bone marrow biopsies from myeloma patients with high (≥6 bone lesions) or low (<3 bone lesions) numbers of bone lesions and found that more CRP protein was present in the bone marrow of myeloma patients with more bone disease (Fig. 8B). Moreover, positive correlations were also found between the levels of serum RANKL (Fig. 8C) or MCP-1 (Fig. 8D) and CRP level. We quantified serum collagen type I C-telopeptide (CTx)–1, which reflects the bone resorption activity of OCs, and observed that CTx and CRP level (Fig. 8E) also positively correlated. These results are clinically significant because they suggest that high levels of CRP may be a key causative factor in the development of the bone disease observed in 80% of patients with myeloma.

**DISCUSSION**

Myeloma is accompanied by bone disease in the vast majority of patients (1, 2). Myeloma cells disrupt the delicate balance between bone formation and resorption, leading to debilitating osteolytic bone lesions (3). Although it is well established that myeloma cells enhance OC differentiation and activity via secreting osteolytic cytokines (17), the mechanism underlying how myeloma cells are regulated and activated to secrete these cytokines remains elusive. Here, we showed that human CRP, which is secreted in elevated amounts by hepatocytes in
response to cytokines (IL-1 or IL-6) derived from myeloma cells in patients (6), may be responsible, at least in part, for activating myeloma cells to promote osteoclastogenesis and inducing bone destruction in vivo. CRP binds with surface CD32/FcγRII, activates p38 MAPK–Twist pathways, and stimulates the secretion of osteolytic cytokines by myeloma cells. Our previous study showed that CRP at a much higher concentration (25 μg/ml) activated ERK and NF-κB but inhibited p38 MAPK (15). Our clinical analyses examining the relationship between the level of serum CRP and the number of osteolytic bone lesions in newly diagnosed patients support this conclusion. Thus, this study reveals a previously unknown mechanism that explains how myeloma cells are activated to promote osteoclastogenesis and induce bone destruction in human myeloma. Our study also suggests that CRP may be a therapeutic target for preventing or treating bone disease in patients with myeloma.

CRP is a sensitive systemic marker of inflammation and tissue damage (6). Its level in the serum is increased in patients with infection, inflammatory disease, necrosis, or malignancy, including myeloma, lymphoma, and carcinoma, and high levels of circulating CRP correlate with poor prognosis in patients with myeloma or lymphoma (9–13). We hypothesized that CRP may not be just a surrogate for tumor burden in myeloma but also plays a central role in myeloma growth, survival, and drug resistance. We reported that adding human CRP to myeloma cultures at levels seen in patients with myeloma or other tumors promoted tumor cell proliferation under stressed conditions and protected tumor cells from apoptosis induced by chemotherapy, IL-6 withdrawal, or serum deprivation in vitro and in vivo (15). The results of this study further showed that CRP may be an important player in myeloma-mediated bone destruction in human myeloma. As inflammation has long been hypothesized to be linked to cancer (21), our studies suggest a possible link between

Fig. 7. Cross-linking CD32 by CRP activates p38 MAPK–Twist in myeloma cells. (A) Western blot for Twist abundance in ARP-1 or MM.1S cells treated with various doses of CRP for 24 hours. (B) Real-time PCR for TWIST mRNA levels in CD32-KD or control myeloma cells cultured with or without CRP. (C) Western blot analysis for dose-dependent effects of CRP on the phosphorylation (p) of p38 mitogen-activated protein kinase (MAPK), extracellular signal–regulated kinase (ERK), and NF-κB in myeloma cells. (D) Western blot analysis for effects of CRP on the phosphorylation of p38 MAPK in CD32-overexpressing (CD32) or knockdown (CD32-KD) ARP-1 cells compared with the respective controls. (E) Real-time PCR analysis of the expression of MCP-1, MIP-1α, and RANKL in ARP-1 cells cultured with or without CRP and the p38 MAPK inhibitor SB202190 (SB20). (F) Western blot analysis for the effect of SB20 on CRP-induced Twist abundance. *P < 0.05, **P < 0.01 by Student’s t test. Data from three independent experiments are shown.

Fig. 8. Relationship between serum CRP level and osteolytic bone lesion number in patients with newly diagnosed myeloma. (A) Correlation between serum CRP level and the number of lytic bone lesions (BLs) in 244 patients with newly diagnosed myeloma. CRP was measured by ELISA, and BLs were detected by radiography (x-ray or magnetic resonance imaging). (B) Representative images of immunohistochemical staining for CRP accumulation in the bone marrow of myeloma patients (three per group) with low (BL < 3) or high (BL ≥ 6) numbers of BLs. Scale bar, 50 μm. (C to E) Correlations between the level of circulating CRP and (C) MCP-1, (D) RANKL, and (E) CTx-1 in 28 randomly selected patients with newly diagnosed myeloma, calculated by Pearson’s correlation coefficient analysis.
inflammation or its products and the pathogenesis and bone destruction in myeloma.

Twist is a basic helix-loop-helix (bHLH) transcriptional factor essential in embryological morphogenesis, and it belongs to the HLH superfamily of proteins, which are involved in a variety of regulatory processes in organisms (22). Initially identified in *Drosophila* where it is involved in mesodermal patterning and morphogenetic movement (23), Twist is a highly conserved protein and a master regulator of morphogenesis. Previous studies have also shown that Twist is important in bone development and is expressed in primary osteoblastic cells (24) and preosteoblasts (25). In situ analysis of murine embryonic development provided evidence that Twist abundance is reduced during endochondral and intramembranous fetal bone development (26). Twist proteins inhibit skeletal development through direct and indirect inhibition of Runx2 (27, 28), a key regulator of osteogenic differentiation. Finally, expression of Twist1 and Twist2 in mesenchymal cells may promote adipogenesis (29). Together, these observations suggest that Twist proteins are important to normal bone marrow stromal cell function. However, Twist is also essential to tumor metastasis. Ectopic expression of Twist proteins results in loss of E-cadherin–mediated cell-cell adhesion, activation of mesenchymal markers, and induction of cell motility; it contributes to metastasis by promoting an epithelial-mesenchymal transition. In human breast cancers, high Twist expression correlates with the presence of invasive lobular carcinoma (30). The role of Twist in bone destruction in myeloma is unclear. Our results indicate that Twist mediates CRP-induced up-regulation of *MCP-1*, RANKL, and *MIP-1α* expression in myeloma cells, leading to enhanced OC-mediated bone resorption. Further studies are needed to elucidate its effect on pathogenesis of myeloma-associated bone disease.

**MATERIALS AND METHODS**

**Primary myeloma cells and myeloma cell lines**

This study was approved by the institutional review board at University of Texas MD Anderson Cancer Center (UTMDACC), and all patients provided written informed consent. Bone marrow aspirates were obtained from newly diagnosed patients with myeloma as part of their routine clinical workup. Patient CD138+ myeloma cells were isolated from the aspirates by magnetic bead sorting (Miltenyi Biotec). The myeloma cell lines ARP-1 and ARK were purchased from the Arkansas Cancer Research Center. Other cell lines were purchased from the American Type Culture Collection. All myeloma cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) (Life Technologies).

**Antibodies and reagents**

Neutralizing antibodies against CRP, MIP-1α, MCP-1, RANKL, and control IgG, and recombinant human CRP, M-CSF, RANKL, and SAP were purchased from R&D Systems. The p38 MAPK–specific inhibitor was purchased from Axon Medchem BV. Except where specified, antibodies for Western blotting analysis were purchased from Cell Signaling Technology.

**In vitro OC formation and function assays**

Human OCs were generated from peripheral blood, CD14 antibody–coated magnetic bead–purified (Miltenyi Biotec) monocytes of healthy blood donors, and cultured in α–minimum essential medium supplemented with 10% FBS with M-CSF (25 ng/ml) (R&D Systems) for 7 days to obtain the precursors of OCs as we previously reported (5). The precursors were then cocultured with myeloma cells in medium without or with a low dose of RANKL (10 ng/ml) for an additional 7 days to induce mature OC formation. To examine the effects of myeloma cells and CRP on OC differentiation, OC precursors (1 × 10^5 cells/ml) were seeded in the wells and cocultured with myeloma cells (0.5 × 10^5 cells/ml) in transwell inserts for 7 days, in OC medium without the addition of RANKL, in the presence or absence of CRP. Cells were fixed with 4% formaldehyde and stained for TRAP by using the Leukocyte Acid Phosphatase Kit (Sigma-Aldrich). At the end of the 2-week culture, culture supernatants were collected and used for quantifying by ELISA (CrossLaps, Biosciences Diagnostics) secreted TRAP5b.

**Knockdown and overexpression in myeloma cells**

The shRNAs specific for *CD32* or *Twist* were purchased from Santa Cruz Technology according to the manufacturer’s instructions. After lentiviral infection, transduced cells were harvested and used to examine CD32 or Twist expression or used for experiments. The cells with *CD32* or Twist knockdown were drug–selected. CRP and CD32 overexpression was achieved using the retroviral expression vector pBABEhybro, according to the manufacturer’s instructions.

**Western blotting analysis**

Cells were harvested and lysed with lysis buffer [50 mM tris (pH 7.5), 140 mM NaCl, 5 mM EDTA, 5 mM NaN3, 1% Triton X-100, 1% NP-40, and 1× protease inhibitor cocktail]. Cell lysates were subjected to SDS–polyacrylamide gel electrophoresis, transferred to a polyvinylidene difluoride membrane, and immunoblotted with antibodies against CRP (R&D Systems) and phosphorylated or nonphosphorylated p38 MAPK (Cell Signaling Technology) at 4°C overnight. Antibodies were diluted according to the manufacturer’s recommendations. The membrane was stripped and reprobed with anti–β-actin antibodies (Sigma-Aldrich) to ensure equal protein loading. Secondary antibodies conjugated to horseradish peroxidase were used for detection and followed by enhanced chemiluminescence (Pierce Biotechnology) and autoradiography.

**Real-time PCR**

Total RNA was isolated with an RNeasy kit (Qiagen). An aliquot of 1 μg of total RNA was subjected to reverse transcription (RT) with SuperScript II (Invitrogen) RT–PCR kit, and 1 ng of the final complementary DNA was applied to real-time PCR amplification with SYBR Green using StepOnePlus real-time PCR system (Life Technologies). The primers used are listed in table S1.

**Myeloma cell apoptosis**

The fraction of apoptotic cells was determined by staining with fluorescein isothiocyanate–conjugated annexin V and propidium iodide and analyzed by flow cytometry (BD LSRFortessa, BD Biosciences) according to the manufacturer’s instructions.

**Mouse models, radiography, histology, and bone histomorphometry**

CB.17 SCID mice were purchased from Harlan. All mice were maintained in American Association of Laboratory Animal Care–accredited facilities, and the studies were approved by the Institutional Animal Care and Use Committee of the UTMDACC. Six- to 8-week-old mice were injected intravenously with (1 × 10^6 cells per mouse) human myeloma cell lines ARP-1 and MM.1S, and myeloma-bearing mice were...
then treated with CRP (20 μg per mouse; twice a week for 6 to 8 weeks) or vehicle (PBS). Serum was collected from mice daily during the treatment and tested for myeloma-secreted M-proteins (human Ig) or their light chains by ELISA.

SCID-hu hosts were developed as described previously (31). Fetal bones (10-mm pieces, purchased from Advanced Bioscience Resources Inc.) were implanted subcutaneously and allowed to become vascularized (6 to 10 weeks). Purified myeloma cells (≥10⁶ cells per mouse) were injected into implanted human bones to establish myeloma (4 to 6 weeks) (n = 5 per group). After 7 days, mice were treated with CRP or SAP (20 μg per mouse) or equal volume of PBS twice a week for 8 weeks. Serum was obtained from the mice weekly and assayed by ELISA for the human M-component.

Mice were x-rayed weekly starting at 1 to 2 weeks after tumor injection. To measure the size of lytic bone lesions, radiographs were scanned with a Faxitron x-ray cabinet (Faxitron x-ray). The total number of osteolytic lesions or area was quantified using ImageJ software (National Institutes of Health). For histological and bone histomorphometric analyses, mice were euthanized, and mouse femurs were fixed in 10% neutral-buffered formalin for 18 hours. To detect mature OCs, a leukocyte acid phosphatase staining kit (Sigma-Aldrich) was used to stain sections with TRAP according to the manufacturer’s instructions. The number of TRAP-positive, multinuclear (>3) OCs per millimeter of bone at the bone-tumor interface was calculated using a computerized image analysis system.

Immunohistochemistry

Formalin-fixed, paraffin-embedded sections of SCID mouse femurs were deparaffinized with xylene and rehydrated to water through a graded alcohol series. Endogenous peroxidase activity was quenched with 3% hydrogen peroxide. Expression of CD138 and CD32 was detected using specific antibodies (R&D Systems and LifeSpan BioSciences Inc.). Signal was detected using secondary biotinylated antibodies and streptavidin/horseradish peroxidase. Chromagen 3,3-diaminobenzidine/H₂O₂ (Dako) was used, and slides were counterstained with hematoxylin. All slides were observed under light microscopy, and images were captured with a SPOT RT camera (Diagnostic Instruments).

ChIP assays

ChIP analysis with anti-Twist was performed using a commercially available kit (Upstate Biotechnology). Immunoprecipitates and total chromatin input were reverse cross-linked, DNA was isolated, and 1-μl DNA was used for PCR with primers specific for the gene promoter region for RANKL and for MCP-1. The primer sequences were as follows: (i) RANKL: forward, CTTGGACCTCCGAAAAGACAG; reverse, ACTCTATTAAACCGGTTCGAGAG; (ii) MCP-1; forward, CTGTCATGCTTCATGATGCTAC; reverse, TCACGTGCTAGACCAAATGAG.

Transfection and luciferase assay

Cells at 50% confluence were transfected in 12-well petri dishes using Lipofectamine (Gibco-BRL). The total amount of DNA was adjusted to 1.0 μg by adding empty vector. We determined luciferase activity by using a luciferase assay system (Promega). As a reference plasmid to normalize transfection efficiency, 25 ng of pRL-CMV plasmid (Promega) was cotransfected in all experiments.

Microarray analysis

We performed the microarray analysis as described previously (32). At least a twofold difference between control myeloma cells and CRP-treated myeloma cells was required. Microarray data have been deposited in the Gene Expression Omnibus (GEO) database (GSE103697).

Statistical analysis

All data are shown as means ± SD. Student’s t test was used to compare various experimental groups; significance was set at an α level of 0.05.


Acknowledgments: We thank C. Talericco (Department of Cancer Biology, Cleveland Clinic) for helpful editorial assistance and the MD Anderson Myeloma Tissue Bank for providing patient samples. Funding: This work was supported by grants from National Cancer Institute (NCI) R01s (CA190863 and CA193362 to Jing Y. and CA138398, CA200539, CA211073, and CA214811 to Q.Y.; an American Cancer Society Research Scholar Grant (127337-RSG-15-069-01-TBG); grants from UTMDACC Institutional Research Grant-Basic Research, Leukemia Research Foundation, and American Society of Hematology and National Natural Science Foundation of China grant no. 81470356 to Jing Y., as well as The Leukemia & Lymphoma Society Translational Research Program (6469-15) and Multiple Myeloma Research Foundation Senior Investigator Award to Q.Y. This work was also supported by NIH/NCI under award number P30CA16672 and used the Small Animal Imaging Facility for radiography and Research Histopathology Facility for histological studies. Author contributions: Conceptualization: Q.Y. and Jing Y.; methodology: Jing Y., Z.L., H.L., J. He, Jianling Y., Q.W., and E.D.; microarray analysis: W.M. and E.D.; providing samples and critical suggestions: P.L., J.D., R.Z.O., and J. Hou; statistical consultation: Z.Y.; writing: Jing Y., H.L., and Q.Y; funding acquisition: Q.Y. and Jing Y. Competing interests: The authors declare that they have no competing interests. Data and material availability: Microarray data have been deposited in the GEO database (GSE103697).
Liver protein instructs bone loss in myeloma

Bone loss is common in patients with multiple myeloma (MM). MM cells activate osteoclasts, cells that degrade bone. The sera of MM patients typically have increased amounts of C-reactive protein (CRP), which is secreted by the liver in response to cytokines associated with tissue inflammation and physiological stress, including those secreted by MM. Using samples from patients, as well as human cell lines and mice bearing human bone grafts and MM cells, Yang et al. found that CRP is not merely a diagnostic marker for MM but that rather it feeds back on MM cells to stimulate the expression and secretion of osteoclast-activating cytokines from MM cells, thereby driving bone loss in patients. These findings suggest that targeting the cyclical CRP signaling axis may reduce or prevent MM-associated bone loss.